Acelyrin INC., a United States-based biopharma company, announced on Thursday, June 10, that it has named Patrick (Pat) Machado, JD as its new director.
Machado has over two decades of experience supporting biopharmaceutical organisations from development through commercialisation. Presently, Machado serves on the boards of Adverum Biotechnologies Inc., Turning Point Therapeutics, Chimerix Inc., Roivant Sciences Ltd., Xenon Pharmaceuticals, Turnstone Biologics, and Arcus Biosciences. He has served as a director of Endocyte, Principia Biopharma and Therachon. He has served as director for a total of 15 public and private biotech companies, with roles including chairing boards, audit, and compensation committees.
He was co-founder and has served as chief business and financial officer, and board member of Medivation, Inc. He has also held the position of senior vice president, finance and business development, chief financial officer, and general counsel of Pro-Duct Health Inc. He has also served as division corporate counsel for Chiron Technologies at Chiron Corporation. He started his career in the corporate finance department as an attorney at Morrison and Foerster LLP.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer